JP2004506658A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004506658A5 JP2004506658A5 JP2002519615A JP2002519615A JP2004506658A5 JP 2004506658 A5 JP2004506658 A5 JP 2004506658A5 JP 2002519615 A JP2002519615 A JP 2002519615A JP 2002519615 A JP2002519615 A JP 2002519615A JP 2004506658 A5 JP2004506658 A5 JP 2004506658A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- muscle
- vegf
- gene encoding
- delivered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000002845 virion Anatomy 0.000 description 6
- 239000002870 angiogenesis inducing agent Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
- 229940126864 fibroblast growth factor Drugs 0.000 description 3
- 102000009088 Angiopoietin-1 Human genes 0.000 description 2
- 108010048154 Angiopoietin-1 Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22605600P | 2000-08-17 | 2000-08-17 | |
| PCT/IB2001/001902 WO2002014487A2 (en) | 2000-08-17 | 2001-08-17 | Adeno-associated virus-mediated delivery of angiogenic factors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004506658A JP2004506658A (ja) | 2004-03-04 |
| JP2004506658A5 true JP2004506658A5 (https=) | 2008-10-09 |
Family
ID=22847367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002519615A Pending JP2004506658A (ja) | 2000-08-17 | 2001-08-17 | アデノ随伴ウイルスを介した血管形成因子のデリバリー |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20020111324A1 (https=) |
| EP (1) | EP1311699B1 (https=) |
| JP (1) | JP2004506658A (https=) |
| AT (1) | ATE366319T1 (https=) |
| AU (1) | AU2001294096A1 (https=) |
| CA (1) | CA2419245A1 (https=) |
| DE (1) | DE60129229T2 (https=) |
| ES (1) | ES2288993T3 (https=) |
| WO (1) | WO2002014487A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2406687A1 (en) * | 2001-11-09 | 2003-05-09 | Transgene S.A. | Chimeric promoters for controlling expression in muscle cells |
| JP2005528362A (ja) * | 2002-03-21 | 2005-09-22 | ユニヴァーシティ オヴ フロリダ | 血管新生の調節法 |
| US20030198620A1 (en) * | 2002-04-16 | 2003-10-23 | Keiya Ozawa | Method of treating amino acid metabolic disorders using recombinant adeno-associated virus virions |
| CN100387723C (zh) * | 2005-12-02 | 2008-05-14 | 浙江大学 | 血管生长素基因重组腺相关病毒载体及制备方法和用途 |
| GB0821834D0 (en) * | 2008-11-28 | 2009-01-07 | Iti Scotland Ltd | Calibration and control method |
| WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
| SG11201703148TA (en) | 2014-11-05 | 2017-05-30 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| CA3193811A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| CN119876138A (zh) | 2014-11-14 | 2025-04-25 | 沃雅戈治疗公司 | 调节性多核苷酸 |
| HK1245326A1 (zh) | 2014-12-12 | 2018-08-24 | Voyager Therapeutics, Inc. | 用於生产scaav的组合物和方法 |
| CA2973096A1 (en) | 2015-01-06 | 2016-07-14 | Cardiovascular Biotherapeutics, Inc. | Angiogenic treatment of ischemic heart disease |
| AU2016220304B2 (en) | 2015-02-16 | 2019-07-25 | Venturis Therapeutics, Inc. | Therapeutic angiogenesis for treating erectile conditions |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| CA3024449A1 (en) | 2016-05-18 | 2017-11-23 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
| CA3024448C (en) | 2016-05-18 | 2025-09-09 | Voyager Therapeutics, Inc. | MODULATING POLYNUCLEOTIDES |
| WO2018044933A1 (en) | 2016-08-30 | 2018-03-08 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| EP3618839A4 (en) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| JP2020518259A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ハンチントン病治療組成物および方法 |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| JP7229989B2 (ja) | 2017-07-17 | 2023-02-28 | ボイジャー セラピューティクス インコーポレイテッド | 軌道アレイガイドシステム |
| JP7221275B2 (ja) | 2017-08-03 | 2023-02-13 | ボイジャー セラピューティクス インコーポレイテッド | Ａａｖを送達するための組成物および方法 |
| US20200263199A1 (en) | 2017-09-29 | 2020-08-20 | Voyager Therapeutics, Inc. | Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery |
| TW202413649A (zh) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| SG11202011296VA (en) | 2018-05-15 | 2020-12-30 | Voyager Therapeutics Inc | Compositions and methods for the treatment of parkinson's disease |
| US12281321B2 (en) | 2018-09-28 | 2025-04-22 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| BR112023001456A2 (pt) | 2020-07-27 | 2023-04-11 | Voyager Therapeutics Inc | Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase |
| US20230285596A1 (en) | 2020-07-27 | 2023-09-14 | Voyager Therapeutics, Inc | Compositions and methods for the treatment of niemann-pick type c1 disease |
| EP4433490A2 (en) | 2021-11-17 | 2024-09-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| AU2023427408A1 (en) | 2023-02-02 | 2025-09-04 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0764893A (ja) * | 1993-08-31 | 1995-03-10 | Canon Inc | ネットワーク・システム |
| US20030148968A1 (en) * | 1995-02-28 | 2003-08-07 | Hammond H. Kirk | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
| US6162796A (en) * | 1995-09-27 | 2000-12-19 | The Rockefeller University | Method for transferring genes to the heart using AAV vectors |
| US6004797A (en) * | 1995-11-09 | 1999-12-21 | Avigen, Inc. | Adenovirus helper-free recombinant AAV Virion production |
| US5858351A (en) * | 1996-01-18 | 1999-01-12 | Avigen, Inc. | Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors |
| WO1997032990A1 (en) * | 1996-03-04 | 1997-09-12 | Targeted Genetics Corporation | Methods for transducing cells in blood vessels using recombinant aav vectors |
| US6013780A (en) * | 1996-09-06 | 2000-01-11 | Technion Research & Development Co. Ltd. | VEGF145 expression vectors |
| JP2002502608A (ja) * | 1998-02-06 | 2002-01-29 | コラテラル・セラピューティックス・インコーポレイテッド | 血管新生促進因子である血管内皮細胞成長因子：ｖｅｇｆの変異体 |
| AU763049B2 (en) * | 1998-12-28 | 2003-07-10 | Arch Development Corporation | Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinantadeno-associated virus vectors |
| EP1016726A1 (en) * | 1998-12-30 | 2000-07-05 | Introgene B.V. | Gene therapy to promote angiogenesis |
| JP2003501092A (ja) * | 1999-06-07 | 2003-01-14 | エドワーズ ライフサイエンシーズ コーポレイション | 標的化新脈管形成 |
| US7223406B2 (en) * | 2000-07-21 | 2007-05-29 | The Regents Of The University Of California | Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder |
-
2001
- 2001-08-17 CA CA002419245A patent/CA2419245A1/en not_active Abandoned
- 2001-08-17 DE DE60129229T patent/DE60129229T2/de not_active Expired - Lifetime
- 2001-08-17 ES ES01974582T patent/ES2288993T3/es not_active Expired - Lifetime
- 2001-08-17 JP JP2002519615A patent/JP2004506658A/ja active Pending
- 2001-08-17 AU AU2001294096A patent/AU2001294096A1/en not_active Abandoned
- 2001-08-17 AT AT01974582T patent/ATE366319T1/de not_active IP Right Cessation
- 2001-08-17 US US09/932,451 patent/US20020111324A1/en not_active Abandoned
- 2001-08-17 WO PCT/IB2001/001902 patent/WO2002014487A2/en not_active Ceased
- 2001-08-17 EP EP01974582A patent/EP1311699B1/en not_active Expired - Lifetime
-
2006
- 2006-05-26 US US11/441,790 patent/US20070128163A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004506658A5 (https=) | ||
| EP1311699B1 (en) | Adeno-associated virus-mediated delivery of angiogenic factors | |
| FI3717636T3 (fi) | Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä | |
| US6753321B2 (en) | Method of modulating neovascularization | |
| JP2005501802A5 (https=) | ||
| JP2001512142A (ja) | 宿主の免疫抑制を介するａａｖベクターの再投与を可能にする方法 | |
| US20180296641A1 (en) | Method to induce neovascular formation and tissue regeneration | |
| US6329348B1 (en) | Method of inducing angiogenesis | |
| US7524493B2 (en) | Nucleic acid constructs cells transformed therewith and methods utilizing same for inducing liver regeneration and alleviation of portal hypertension | |
| US20070232541A1 (en) | Methods of regulating angiogenisis through stabilization of pedf | |
| AU2001283108A1 (en) | Manipulation of arterial-venous identity | |
| JP2002533359A5 (https=) | ||
| Sellner et al. | Generation of efficient human blood progenitor–targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells | |
| JP2019070001A (ja) | 肝細胞増殖因子及びストローマ細胞由来因子１αを用いた末梢動脈疾患の予防または治療用組成物 | |
| JPWO2022186282A5 (https=) | ||
| JP2021513871A5 (https=) | ||
| WO2023111106A1 (en) | Fukutin related protein gene transfer increase using modified itr sequences | |
| WO1999048537A1 (en) | Use of scatter factor to enhance angiogenesis | |
| EP4198048A1 (en) | Calpain-3 gene transfer increase using modified itr sequences | |
| Kizana | Therapeutic prospects of cardiac gene transfer | |
| EP1870473A1 (en) | Adeno-associated virus-mediated delivery of angiogenic factors | |
| JP2021527418A (ja) | ジストログリカノパチーおよびラミニン欠損筋ジストロフィーを治療するための組換えアデノ随伴ウイルス生成物および方法 | |
| Zhang et al. | Construction and expression of Ad-EGFP-MCP-1 vector | |
| ZACCHIGNA et al. | IN VIVO GENE TRANSFER WITH AAV VECTORS AS A TOOL TO UNDERSTAND GENE FUNCTION IN BLOOD VESSEL FORMATION | |
| Su et al. | 925. pVGI. 1 (VEGF2) Biodistribution in Swine Following Injection into Anterior Wall of the Left Ventricle Using the Stiletto™ Endocardial Direct Injection Catheter System |